Evidence map›Paper›PMID 39456085›Full record

ReviewJournal of nanobiotechnology2024

The wonders of X-PDT: an advance route to cancer theranostics.

Asim Mushtaq, Muhammad Zubair Iqbal, Jianbin Tang, Wenjing Sun

Abstract readReview
In one paragraph

Review in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. The Immune Microenvironment in Liver Cancer: From Analysis to Targeting.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Asim MushtaqInstitute for Intelligent Bio/Chem Manufacturing (iBCM), ZJU-Hangzhou Global Scientific and Technological Innovation Center, Hangzhou, 311200, Zhejiang, China.
Muhammad Zubair IqbalInstitute of Smart Biomedical Materials, School of Materials Science and Engineering, Zhejiang Sci-Tech University, Hangzhou, 310018, China.
Jianbin TangInstitute for Intelligent Bio/Chem Manufacturing (iBCM), ZJU-Hangzhou Global Scientific and Technological Innovation Center, Hangzhou, 311200, Zhejiang, China.
Wenjing SunInstitute for Intelligent Bio/Chem Manufacturing (iBCM), ZJU-Hangzhou Global Scientific and Technological Innovation Center, Hangzhou, 311200, Zhejiang, China. sunwj0102@zju.edu.cn.

Funding

the 2023 Hangzhou West Lake Pearl Project Leading Innovative Youth Team Project TD2023017the National Natural Science Foundation of China T2293753the Postdoctoral funding Grant 02080100-K3F113001
6 · The paper itself

Abstract

Global mortality data indicates cancer as the second-leading cause of death worldwide. Therefore, there's a pressing need to innovate effective treatments to address this significant medical and societal challenge. In recent years, X-ray-induced photodynamic therapy (X-PDT) has emerged as a promising advancement, revolutionizing traditional photodynamic therapy (PDT) for deeply entrenched malignancies by harnessing penetrating X-rays as external stimuli. Recent developments in X-ray photodynamic therapy have shown a trend toward minimizing radiation doses to remarkably low levels after the proof-of-concept demonstration. Early detection and real-time monitoring are crucial aspects of effective cancer treatment. Sophisticated X-ray imaging techniques have been enhanced by the introduction of X-ray luminescence nano-agents, alongside contrast nanomaterials based on X-ray attenuation. X-ray luminescence-based in vivo imaging offers excellent detection sensitivity and superior image quality in deep tissues at a reasonable cost, due to unhindered penetration and unimpeded auto-fluorescence of X-rays. This review emphasizes the significance of X-ray responsive theranostics, exploring their mechanism of action, feasibility, biocompatibility, and promising prospects in imaging-guided therapy for deep-seated tumors. Additionally, it discusses promising applications of X-PDT in treating breast cancer, liver cancer, lung cancer, skin cancer, and colorectal cancer.

Indexed as

NeoplasmsPhotochemotherapyTheranostic NanomedicineAnimalsHumansPhotosensitizing AgentsX-RaysPhotosensitizing AgentsDeep tumorsROSTheranosticX-PDTX-ray responsive imaging

Identifiers

PMID39456085
PMCPMC11520131

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.